An interventional study of protein supplementation in Addiction, sponsored by Centre Hospitalier de PAU. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.
Sponsored by Centre Hospitalier de PAU · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies in Behavior, Addictive with a site in France — 33 open to participants now, 34 under way, none of them phase 3. Behavior, Addictive · France.
Among the 77 studies in Behavior, Addictive with a site in France, this one is the 31st largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2024, is one of 33 with no phase, and was the 56th registered.
522 studies on the registry are indexed under Behavior, Addictive; 125 are open to participants now.
Browse Behavior, Addictive studies →33 of the 77 studies in Behavior, Addictive with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18+
University of Bordeaux · Sites in France
Ages 18+ · Healthy volunteers
Université de Reims Champagne-Ardenne · Sites in France
Ages 18–65 · Healthy volunteers
University of Bordeaux · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 81 Behavior, Addictive studies recruiting now, 45 (56%) set no upper age limit and 34 (42%) stop at 75 or younger; 7 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 62 across 399 interventional studies indexed under Behavior, Addictive.
Median enrollment 88 across the 34 interventional studies, 170 across the 43 observational. Of the 31 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 77 has an industry lead sponsor. The 10 most frequent:
Centre Hospitalier de PAU is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Centre Hospitalier de PAU has 1 study filed under Behavior, Addictive — fewer than ten, so there is no comparison to draw.
5 of the studies in Behavior, Addictive with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07421765Centre Hospitalier Universitaire de NīmesInteraction Between Atypical Work Schedules and/or Idel Time at Work on At-risk Gambling Practices | 2027-02 |
| NCT05609474Hôpital le VinatierTrajectories and Reactions of Users and Relatives Consulting French Youth Addiction Services | 2027-02-15 |
| NCT07193914Centre Hospitalier Universitaire de NīmesAdaptation of the ECCCLORE Program for Patients With Addictive and Traumatic Problems | 2027-03 |
| NCT07819851Centre Hospitalier Universitaire de NiceA Study of the Correlation Between the Severity of Substance Use Disorder and the Intensity of Dependence on Generative Artificial Intelligence | 2027-06-05 |
| NCT07788352Université de Reims Champagne-Ardennetéléwork and Consumer Behavior: Longitudinal Study | 2027-07-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 77 studies in Behavior, Addictive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Moncentric pilot study conducted in the addictology department of the Pau Hospital, designed to demonstrate the benefit of protein supplementation on craving in patients with a substance use disorder at the start of their treatment for addiction.
This study will be conducted according a crossover design with a one-week phase with protein supplementation (P) and a one-week phase without protein supplementation (SP).
Addiction is a chronic psychiatric disorder characterised by the loss of control over the use of rewarding substances or behaviours, despite the accumulated damage. Craving, defined as an irrepressible, obsessive craving, is a key early symptom of addiction. Protein supplementation could reduce this craving. Nutritional abnormalities aggravate addictions but no study have directly assessed the impact of protein supplementation on craving. Evidence suggests that protein supplementation reduces cravings for sugary and hyperpalatable foods, which could extend to rewarding substances. The hypothesis is that this supplementation reduces the intensity, duration and frequency of craving in withdrawal patients by influencing dopaminergic reward circuits.
Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time (8am and 4pm).
Patients will be enrolled at the admission to the addiction unit. They will be assessed psychologically, addictologically and nutritionally for one week and then will be randomised. Patients will be asked to assess their cravings, dietary needs, consumption of addictive substances and palatable foods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1 week with protein supplementation (P) then one week without protein supplementation (SP)
Dietary Supplement: protein supplementation
1 week without protein supplementation (SP) then one week with protein supplementation (P)
Dietary Supplement: protein supplementation
Protein supplementation takes the form of a powder sachet mixed with yoghurt or compote. It will be given twice a day, at the same time.
Evolution of craving for the main substance
Evaluation of the evolution of craving for the main substance in patients with a substance use disorder in association with protein supplementation. It will be a self-assessment by the patient, using a visual analogue craving scale ranging from 1 'no craving' to 7 'extreme craving'.
Time frame: This outcome will be assessed twice a day (morning and afternoon) from day 8 to day 21, during the period with and without protein supplementation.
Food craving evolution
Food craving will be assessed by patient self-assessment using a visual analogue craving scale ranging from 1 'no craving' to 7 'extreme craving'.
Time frame: This outcome will be assessed twice a day (morning and evening) from Day 8 to Day 21 during the period with and without protein supplementation.
Consumption of hyperpalatable foods
Consumption of hyperpalatable foods will be assessed by patient self-evaluation, twice a day from D8 to D21 during the period with and without protein supplementation, using a visual scale assessing the extent to which the patient consumed hyperpalatable foods outside of meals, this scale ranging from 1 'not at all' to 7 'very much'.
Time frame: This outcome will be assessed every day from Day 8 to Day 21 during the period with and without protein supplementation.
Influence of the severity of addiction
Influence of the severity of addiction measured using the Addiction Severity Index (ASI) questionnaire
Time frame: Evaluation at the inclusion
Influence of psychiatric comorbidities
Influence of psychiatric comorbidities (mood disorders and anxiety disorders) assessed using the MINI (Mini International Neuropsychiatric Interview)
Time frame: Evaluation at the inclusion
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2024 to primary completion in Sep 2025, 11 months.
Of 148 non-industry interventional studies with no phase under Behavior, Addictive, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 42. This study's 11 months is below that.
Counting every sponsor, half of 156 studies reached it within 26 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de PAU